JPMorgan Chase & Co. Boosts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

JPMorgan Chase & Co. grew its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,001,397 shares of the company’s stock after buying an additional 37,844 shares during the quarter. JPMorgan Chase & Co. owned 1.46% of Taysha Gene Therapies worth $6,033,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TSHA. Creative Planning bought a new stake in Taysha Gene Therapies during the third quarter worth $28,000. China Universal Asset Management Co. Ltd. increased its position in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at $85,000. Scientech Research LLC bought a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth $97,000. Finally, SG Americas Securities LLC purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth about $129,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Up 0.6 %

Taysha Gene Therapies stock opened at $1.63 on Thursday. The firm has a 50 day simple moving average of $2.13 and a 200 day simple moving average of $2.12. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 1-year low of $1.19 and a 1-year high of $4.32. The firm has a market capitalization of $334.06 million, a price-to-earnings ratio of 2.59 and a beta of 0.95.

Analysts Set New Price Targets

TSHA has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Monday, January 6th. Canaccord Genuity Group increased their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.